Logo image
2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Journal article   Open access   Peer reviewed

2018 American Heart Association Focused Update on Advanced Cardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care

Ashish R. Panchal, Katherine M. Berg, Peter J. Kudenchuk, Marina Del Rios, Karen G. Hirsch, Mark S. Link, Michael C. Kurz, Paul S. Chan, Jose G. Cabanas, Peter T. Morley, …
Circulation (New York, N.Y.), Vol.138(23), pp.E740-E749
12/04/2018
DOI: 10.1161/CIR.0000000000000613
PMCID: PMC7324904
PMID: 30571262
url
https://doi.org/10.1161/CIR.0000000000000613View
Published (Version of record) Open Access

Abstract

Antiarrhythmic medications are commonly administered during and immediately after a ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. However, it is unclear whether these medications improve patient outcomes. This 2018 American Heart Association focused update on advanced cardiovascular life support guidelines summarizes the most recent published evidence for and recommendations on the use of antiarrhythmic drugs during and immediately after shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest. This article includes the revised recommendation that providers may consider either amiodarone or lidocaine to treat shock-refractory ventricular fibrillation/pulseless ventricular tachycardia cardiac arrest.
Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Life Sciences & Biomedicine Peripheral Vascular Disease Science & Technology

Details

Logo image